Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

New England Journal of Medicine

Volumn 357, Issue 17, 2007, Pages 1695-1704

  Vermorken, Jan B ^a   Remenar, Eva ^b   Van Herpen, Carla ^c   Gorlia, Thierry ^d   Mesia, Ricard ^e   Degardin, Marian ^f   Stewart, John S ^g   Jelic, Svetislav ^h   Betka, Jan ⁱ   Preiss, Joachim H ^j   Van Den Weyngaert, Danielle ^k   Awada, Ahmad ^l   Cupissol, Didier ^m   Kienzer, Heinz R ⁿ   Rey, Augustin ^o   Desaunois, Isabelle ^d   Bernier, Jacques ^p   Lefebvre, Jean Louis ^f  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f CENTRE OSCAR LAMBRET   (France)

^g CHARING CROSS HOSPITAL   (United Kingdom)

^h INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^j Caritasklinik St Theresia   (Germany)

^k MIDDELHEIM HOSPITAL   (Belgium)

^l JULES BORDET INSTITUTE   (Belgium)

^m CENTRE VAL D AURELLE   (France)

ⁿ KAISER FRANZ JOSEF HOSPITAL   (Austria)

^o SANOFI   (France)

^p CLINIQUE DE GENOLIER   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL PAIN; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; HYPERSENSITIVITY; INFECTION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ODYNOPHAGIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 35548966042     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa071028     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Seiwert TY, Cohen EEW. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005;92:1341-8.
3. Lefebvre J-L. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005;16:Suppl 6:vi7-vi12.
4. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
5. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-72.
6. Adelstein DJ, Li Y, Adams G, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
7. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004;96:1714-7.
8. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 2000;83:1594-8.
9. Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-8.
10. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-55.
11. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist 2000;5:199-208.
12. Pignon JP, Syz N, Posner M, et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004;15:331-40.
13. Freedman LS, White SJ. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976;32:691-4.
14. Bernier J, Coens C, Remenar E, et al. Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:18S. abstract.
15. Slud EV, Byar DP, Green SB. A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data. Biometrics 1984;40:587-600.
16. Schrijvers D, Van Herpen C, Kerger J, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 2004;15:638-45.
17. Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 2005;10:Suppl 3:11-9.
18. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
19. Hitt R, López A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-45. [Erratum, J Clin Oncol 2006;24:1015.]
20. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54.
21. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28.
22. Paccagnella A, Buffoli A, Koussis H, et al. Randomized phase II trial of concomitant CT/RT versus TPF followed by concomitant CT/RT in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 2006;24:18S. abstract.
23. Hitt R, Grau J, Lopez-Pousa A, et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. CRT alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2006;24:18S. abstract.
24. Adelstein DJ, LeBlanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 2006;24:2624-8.